New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 8, 2013
06:16 EDTSNY, GERN, INCYIncyte still well positioned in myelofibrosis, says Jefferies
Jefferies believes Incyte (INCY) remains well positioned in myelofibrosis following data abstracts on two competitors. The firm says Geron's (GERN) data for imetelstat looks promising but comes with caveats, while Incyte's Jakafi is a strong competitor to Sanofi's (SNY) fedratinib. Jefferies keeps a Buy rating on shares of Incyte.
News For INCY;GERN;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2015
17:23 EDTGERNGeron files $250M mixed securities shelf
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTSNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
August 23, 2015
12:35 EDTINCYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
08:55 EDTINCYIncyte management to meet with JPMorgan
Subscribe for More Information
August 20, 2015
11:33 EDTSNYLeerink major pharmaceuticals analyst holds an analyst/industry conference call
Subscribe for More Information
August 18, 2015
08:41 EDTINCYIncyte shares poised to advance further, says Argus
Argus believes that Incyte's new products make its revenue outlook "promising." The firm thinks the company's "deep" pipeline could enable it to become a takeover target. Argus keeps a Buy rating on the shares.
August 17, 2015
14:11 EDTINCYIncyte reveals favorable early data on IDO inhibitor, says Cowen
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use